Published in World J Gastroenterol on December 07, 2013
RELATIONSHIP BETWEEN UVEITIS, DIFFERENT TYPES OF VIRAL HEPATITIS, AND LIVER CIRRHOSIS: A 12-Year Nationwide Population-Based Cohort Study. Retina (2016) 0.75
Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals. GMS Ophthalmol Cases (2016) 0.75
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (1989) 37.89
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science (1989) 18.79
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
Course and outcome of hepatitis C. Hepatology (2002) 6.51
Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect (2011) 6.48
Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat (1999) 6.42
Diabetic retinopathy. N Engl J Med (2012) 5.79
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology (2007) 5.53
Side effects of therapy of hepatitis C and their management. Hepatology (2002) 5.18
Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat (2006) 5.10
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology (2007) 4.44
Interferon-associated retinopathy. Arch Ophthalmol (1993) 2.73
Hypertensive retinopathy. N Engl J Med (2004) 2.65
Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology (1996) 2.22
Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol (1996) 2.14
Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis. J Hepatol (2005) 1.73
Clinical guidelines on the management of hepatitis C. Gut (2001) 1.72
Neurovisual impairment: a frequent complication of alpha-interferon treatment in chronic viral hepatitis. Hepatology (1998) 1.67
New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology (1997) 1.62
Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol (1996) 1.60
2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int (2012) 1.47
Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. Ophthalmology (2003) 1.46
Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C. World J Gastroenterol (2007) 1.46
Is screening for interferon retinopathy in hepatitis C justified? Br J Ophthalmol (2004) 1.37
Oculomotor nerve paralysis induced by alpha II-interferon. Acta Neurol Belg (1990) 1.27
Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa. Br J Ophthalmol (1995) 1.26
Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. Am J Gastroenterol (1998) 1.26
Interferon-associated combined branch retinal artery and central retinal vein obstruction. Retina (2003) 1.21
Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol (2001) 1.19
Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C. World J Gastroenterol (2006) 1.12
Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy. J Viral Hepat (2003) 1.08
Anterior ischemic optic neuropathy associated with pegylated interferon therapy for chronic hepatitis C. Ocul Immunol Inflamm (2009) 1.07
Vogt-Koyanagi-Harada disease associated with interferon-A and ribavirin therapy for chronic hepatitis C infection. J Infect (2005) 1.07
Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol (1997) 1.07
Interferon-associated retinopathy in a uniform regimen of natural interferon-alpha therapy for chronic hepatitis C. Liver (2001) 1.06
HCV treatment--no more room for interferonologists? N Engl J Med (2013) 1.03
Branch retinal vein thrombosis and visual loss probably associated with pegylated interferon therapy of chronic hepatitis C. World J Gastroenterol (2006) 1.02
Ocular complications with high-dose interferon alpha in chronic active hepatitis. Eye (Lond) (1999) 1.02
Hepatitis C. Semin Liver Dis (2009) 1.01
Interferon alfa-associated anterior ischemic optic neuropathy. Ophthalmology (2010) 0.96
Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin. Jpn J Ophthalmol (2009) 0.92
Retinal vein thrombosis associated with pegylated-interferon and ribavirin combination therapy for chronic hepatitis C. World J Gastroenterol (2006) 0.92
Retinal circulatory changes associated with interferon-induced retinopathy in patients with hepatitis C. Invest Ophthalmol Vis Sci (2007) 0.91
Development of neovascular glaucoma in the course of interferon alfa therapy for hepatitis type C. Br J Ophthalmol (1994) 0.90
Interferon alfa induces leukocyte capillary trapping in rat retinal microcirculation. Arch Ophthalmol (1996) 0.89
Retinopathy is not the only ocular symptom: myasthenia gravis in association with interferon therapy. Br J Ophthalmol (2005) 0.88
Vascular ophthalmological side effects associated with antiviral therapy for chronic hepatitis C are related to vascular endothelial growth factor levels. Antivir Ther (2006) 0.88
Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography. Jpn J Ophthalmol (2005) 0.87
Retinal toxicity during pegylated alpha-interferon therapy for chronic hepatitis C: a multifocal electroretinogram investigation. Aliment Pharmacol Ther (2005) 0.87
Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection. Aliment Pharmacol Ther (2009) 0.86
Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C. Korean J Hepatol (2011) 0.86
Optic tract neuropathy complicating low-dose interferon treatment. J Hepatol (1994) 0.86
Mixed vascular occlusion in a patient with interferon-associated retinopathy. Case Rep Ophthalmol (2011) 0.85
A prospective study of change in visual function in patients treated with pegylated interferon alpha for hepatitis C in the UK. Br J Ophthalmol (2007) 0.85
Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis. J Investig Med (1995) 0.84
Sarcoidosis presenting with granulomatous uveitis induced by pegylated interferon and ribavirin therapy for Hepatitis C. Intern Med J (2008) 0.83
Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes? J Ocul Pharmacol Ther (2012) 0.83
Interferon-alpha2a and Vogt-Koyanagi-Harada disease: a double-edged sword? Int Ophthalmol (2007) 0.83
Interferon-alpha-associated presumed ocular sarcoidosis. Graefes Arch Clin Exp Ophthalmol (2008) 0.81
Pegylated-interferon-associated retinopathy in chronic hepatitis patients. Ophthalmologica (2009) 0.81
Cystoid macular edema and visual loss as sequelae to interferon alpha treatment of systemic hepatitis C. Indian J Ophthalmol (2010) 0.80
Visual loss during interferon-alpha therapy in hepatitis C virus infection. J Hepatol (2002) 0.80
Outcome of retinopathy in chronic hepatitis C patients treated with peginterferon and ribavirin. Dig Dis Sci (2009) 0.79
Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C. Korean J Hepatol (2009) 0.79
Irreversible anterior ischemic optic neuropathy complicating interferon alpha and ribaverin therapy. Int J Hepatol (2010) 0.79
Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirin. Int J Infect Dis (2011) 0.79
Pegylated interferon-associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screening. Hepatology (2012) 0.79
Central retinal vein occlusion in hypertensive patients with chronic hepatitis C treated with interferon alpha and ribavirin. Jpn J Ophthalmol (2008) 0.77
Retinopathy in chronic hepatitis C patients during interferon treatment: a case report. Infez Med (2010) 0.76
Anterior uveitis after treatment of hepatitis C with alpha interferon: the recurrence of a previous inflammatory process due to presumed ocular toxocariasis. Ocul Immunol Inflamm (2012) 0.76
Symptomatic interferon retinopathy successfully treated by hypertension management. Br J Ophthalmol (2007) 0.76
Neurovisual complications of interferon-alpha therapy. Hepatology (1998) 0.76
Pegylated interferon-associated retinopathy in chronic hepatitis C patients. Jpn J Ophthalmol (2006) 0.76
Interferon-induced central retinal vein thrombosis. J Coll Physicians Surg Pak (2012) 0.76
Retinopathy associated with pegylated interferon and ribavirin causing permanent visual impairment in a patient with chronic hepatitis C. Ophthalmic Surg Lasers Imaging (2011) 0.76
Relapse of Vogt-Koyanagi-Harada Disease during Interferon-α and Ribavirin Therapy in a Case of Chronic Viral Hepatitis C. Case Rep Ophthalmol (2011) 0.76
Branch retinal artery occlusion and central retinal vein occlusion associated with pegylated interferon plus ribavirin combination therapy for chronic hepatitis C. Cutan Ocul Toxicol (2011) 0.76